Back to Search
Start Over
Effects of once‐weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN‐6 trial.
- Source :
-
Diabetes, Obesity & Metabolism . Apr2023, Vol. 25 Issue 4, p1117-1120. 4p. - Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 14628902
- Volume :
- 25
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Diabetes, Obesity & Metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 162243095
- Full Text :
- https://doi.org/10.1111/dom.14941